April 15–21, 2026 marks the 32nd National Anti-Cancer Week, themed “Early Prevention, Early Screening, Early Treatment – United Hand in Hand Against Cancer.” The campaign aims to comprehensively raise public awareness of cancer prevention and control and mitigate cancer-related harm through etiological prevention, screening and treatment, social co-governance, and science popularization and education. As a biopharmaceutical company dedicated to the R&D and manufacturing of innovative cancer therapies, Alphamab Oncology actively pursues its mission of “to enable long-term, high-quality survival for cancer patients”, and contributes to the advancement of cancer prevention and treatment efforts.
Data from the World Health Organization (WHO) shows that approximately 20 million new cancer cases are diagnosed globally each year, with China accounting for about 23.7% of these new cases, reflecting the severe challenges in cancer prevention and treatment. Nevertheless, scientific research has indicated that around 40% of tumors can be prevented through healthy lifestyles, 30% can be clinically cured via early screening and diagnosis, and another 30% can have prolonged survival through standardized treatment.
Leveraging its proprietary core technology platforms, Alphamab Oncology continues to advance differentiated, innovative therapies that are more effective, safer, and more convenient. The company has built a product pipeline centered on antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies:
● Envafolimab (KN035): The world’s first subcutaneous PD-(L)1 inhibitor, already approved for marketing. Its pan-tumor coverage and 30-second subcutaneous administration represent a significant breakthrough in enhancing the convenience and accessibility of cancer treatment, substantially improving patients’ treatment experience.
● Anbenitamab (KN026): It has achieved robust progression‑free survival (PFS) and overall survival (OS) benefits in second- or third-line HER2-positive gastric cancer. The compelling efficacy data has fully demonstrated the clinical value of "China-innovated medicine" on the global academic stage. The new drug application (NDA) for this indication is currently under review, with the potential to reshape the treatment landscape for HER2-positive gastric cancer. In addition, multiple combination therapies for new indications are being accelerated.
● Bispecific ADC innovative drugs: JSKN003, JSKN016, and JSKN033 cover a wide range of high‑incidence tumor types including breast cancer, ovarian cancer, colorectal cancer, gastric cancer, lung cancer, and cervical cancer. Five studies are currently in Phase III clinical trials, demonstrating excellent efficacy and safety profiles, and promising to overcome challenges of tumor heterogeneity and drug resistance, offering transformative treatment options for patients. Meanwhile, several bispecific ADCs and dual‑payload ADCs are advancing rapidly in clinical studies, continuously enriching the innovative product portfolio.
Throughout the R&D process, we always place patients at the core. Every innovative drug developed and every technological breakthrough achieved stems from deep insight into clinical needs and more importantly, from our persistent pursuit of “to enable long-term, high-quality survival for cancer patients.” We deeply understand that behind every cancer patient lies the hope of an entire family. Therefore, we strictly uphold quality standards, rigorously managing every step of drug development and manufacturing to ensure each drug is safe and effective, safeguarding patients' lives and health.
Furthermore, Alphamab Oncology actively responds to the national cancer prevention and treatment strategy, taking the initiative to participate in science popularization and public welfare assistance activities. We strive to raise the public awareness of cancer prevention and control and promote widespread knowledge of cancer prevention. We aim to help more people understand the importance of "Early Prevention, Early Screening, Early Treatment", and enable more cancer patients to access high-quality and accessible innovative treatment options.
Technological innovation injects new momentum into cancer treatment. On the 32nd National Anti-Cancer Week, we call on all sectors of society to pay attention to cancer prevention and treatment. Alphamab Oncology will continue to be driven by innovation, deepen research into differentiated cutting‑edge therapies, enable cancer patients to benefit from high‑quality innovative medicines, and work together to build a healthier future for China.
About Alphamab Oncology
Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.
One product has received market approval: Envafolimab (KN035, brand name: 恩维达®), the world's first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Five bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.
Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, enabling patients to achieve long-term, high-quality survival and delivering China-innovated cancer therapies to benefit patients worldwide.
Alphamab Oncology Forward-Looking Statements
This press release contains statements related to our future business，financial performance and future events involving Alphamab Oncology that may constitute forward-looking statements. These statements include projections and estimates and relevant assumptions, statements regarding plans and expectations and statements regarding future activities, operations and performance. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," or words of similar meaning. Such statements are based on the certain assumptions of Alphamab Oncology’s management and business operations, which are subject to various risks and uncertainties, including but not limited to political, economic, legal and business environment. The actual results, performance or achievements of Alphamab Oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statements. Unless otherwise required by applicable laws, Alphamab Oncology does not undertake obligation to publicly update any forward-looking statement nor liability for the failure to materialize such forward-looking statements, whether because of new information, future events or otherwise.
Pharmaceutical Information Statements
Alphamab Oncology does not recommend the clinical use of any already approved or under-development drugs/indications. Any information contained in this press release should not be regarded as any drug application, promotion or advertisement.
